Cargando…

Favipiravir: Lack of efficacy during the treatment with SARS-CoV-2 pneumonia: case report

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051754/ http://dx.doi.org/10.1007/s40278-022-14155-7

Ejemplares similares

Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
por: Solaymani-Dodaran, Masoud, et al.
Publicado: (2021)

Favipiravir: Lack of efficacy following off-label treatment: case report
Publicado: (2021)

Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
por: Hashemian, Seyed MohammadReza, et al.
Publicado: (2022)

Chloroquine/favipiravir/rituximab: COVID-19-pneumonia, off-label use and lack of efficacy: case report
Publicado: (2022)

Favipiravir/methylprednisolone: Off-label use and lack of efficacy: case report
Publicado: (2022)

Colchicine/favipiravir/prednisolone: Lack of efficacy and off label use: case report
Publicado: (2021)

Azithromycin/favipiravir/hydroxychloroquine: Lack of efficacy and off-label use: case report
Publicado: (2021)

Ceftriaxone/favipiravir/vancomycin: Lack of efficacy and off-label use: case report
Publicado: (2022)

Favipiravir: Hyperuricaemia and lack of efficacy following off-label use: 2 case reports
Publicado: (2022)

Favipiravir use for SARS CoV-2 infection
por: Boretti, Alberto
Publicado: (2020)

Favipiravir: Lack of efficacy secondary to off label use in COVID-19: Case report: case report
Publicado: (2021)

Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey
por: ERDEM, Hüseyin Aytaç, et al.
Publicado: (2021)

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2021)

Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition
por: Takahashi, Hidenori, et al.
Publicado: (2020)

Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir
por: Peng, Qi, et al.
Publicado: (2021)

Convalescent-anti-SARS-CoV-2-plasma/heparin: Lack of efficacy following an off-label treatment: case report
Publicado: (2022)

Mycophenolate mofetil/prednisolone/rituximab: SARS-CoV-2 infection and lack of efficacy: 2 case reports
Publicado: (2022)

Multiple drugs: Long-term persistence of the SARS-CoV-2 virus; lack of efficacy: case report
Publicado: (2022)

Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico
por: Sada, Mitsuru, et al.
Publicado: (2020)

Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates
por: Marlin, Romain, et al.
Publicado: (2022)

Rituximab: SARS-CoV-2 pneumonia: case report
Publicado: (2021)

Immunosuppressants: SARS-CoV-2 pneumonia and SARS-CoV-2 infection: 2 case reports
Publicado: (2021)

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity
por: Kaptein, Suzanne J. F., et al.
Publicado: (2020)

Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19)
por: McCullough, Peter A.
Publicado: (2020)

Model of the RNA Polymerase Complex of the SARS-CoV-2 Virus with Favipiravir
por: Polyakov, I. V., et al.
Publicado: (2021)

A case of COVID-19 pneumonia successfully treated with favipiravir (Avigan) in which serum SARS-CoV-2 RNA detected by LAMP method was clinically useful
por: Hirouchi, Takatomo, et al.
Publicado: (2021)

Convalescent-anti-SARS-CoV-2-plasma: Lack of efficacy following off-label use: case report
Publicado: (2021)

Convalescent-anti-SARS-CoV-2-plasma: Lack of efficacy following off-label use: case report
Publicado: (2022)

Ocrelizumab: SARS-CoV-2 pneumonia: 2 case reports
Publicado: (2020)

Detection of SARS-CoV-2 pneumonia: two case reports
por: Seibert, Felix S., et al.
Publicado: (2020)

Convalescent anti SARS-CoV-2 plasma/norepinephrine/tocilizumab: Lack of efficacy and off-label use: case report
Publicado: (2021)

Convalescent-anti-SARS-CoV-2-plasma/dexamethasone/remdesivir: Off-label use and lack of efficacy: case report
Publicado: (2021)

Antibacterials/convalescent-anti-SARS-CoV-2-plasma/hydroxychloroquine: Off-label use and lack of efficacy: case report
Publicado: (2022)

Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase
por: Shannon, A., et al.
Publicado: (2020)

Mechanism of action of favipiravir against SARS-CoV-2: Mutagenesis or chain termination?
por: Zhao, Lei, et al.
Publicado: (2021)

Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir
por: Negru, Paul Andrei, et al.
Publicado: (2022)

Favipiravir: Hyperuricaemia: case report
Publicado: (2021)

Mycoplasma pneumoniae co-infection with SARS-CoV-2: A case report
por: Chaudhry, Rama, et al.
Publicado: (2021)

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
por: Abdelnabi, Rana, et al.
Publicado: (2021)

SARS-CoV-2 pneumonia with large pneumothorax—a case report
por: Hassan, Muhammad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_slmth6lvq066sj7n1s7guf9pnu